The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey

Noia, Vincenzo Di; Renna, Davide; Barberi, Vittoria; Civita, Mattia Di; Riva, Federica; Costantini, Giulia; Aquila, Emanuela Dell'; Russillo, Michelangelo; Bracco, Domenico; Malfa, Antonia Marina La; Giannarelli, Diana; Cognetti, F.

doi:10.1016/j.ejca.2021.05.006

Cited by 52 publications

(47 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From March 1st to 20th, 2021, the BNT162b2 was proposed to 914 CP, of whom 816 (89.3%) accepted to get vaccinated 13 Of the 781 CP (95.7%) tested for seroprevalence at baseline, 29 (3.7%) had a value of anti-S IgG >15 AU/ml, of whom 11 had a known history of COVID-19. The serological response rate (RR) significantly increased from TP0 (2.6%) to TP1 (59.8%)(p<0.0001) and from TP1 to TP2 (59.8% vs 94.2%, p<0.0001), using 15 AU/ml as cut-off (Fig.…”

Section: Resultsmentioning

confidence: 99%

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Noia

Pimpinelli

Renna

et al. 2021

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

The introduction of COVID-19 vaccines within a very short time represents a triumph of modern medicine. However, patients with cancer were mostly excluded from the registrative phase III trials of COVID-19 vaccine and only small clinical studies evaluating the immunogenicity of the vaccines in this frail population have been available. In this large prospective cohort study including 816 patients, we assessed the reliable impact of COVID-19 vaccination in patients with cancer in comparison with a matched-control group of health-care workers. This clinical issue is very relevant since cancer patients are particularly vulnerable to COVID-19-related complications and death and thus are considered as high priority subjects for COVID-19 vaccination. Moreover, we explored clinical characteristics which could potentially affect the immunogenicity of the vaccine to formulate helpful evidence-based recommendation for a safe and effective vaccination.Research.

show abstract

Section: Resultsmentioning

confidence: 99%

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Noia

Pimpinelli

Renna

et al. 2021

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is in line with two studies from Tunisia and Italy. Of the respondents who chose not to be vaccinated, 33.1% and 48.1%, respectively, were concerned about side effects or adverse events associated with the vaccine (Mejri et al 2022 , Di Noia et al 2021 ). In contrast, the major study on the safety profile of Comirnaty® (BioNTech/Pfizer) with a total of N = 43,448 participants portrayed side effects characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache.…”

Section: Discussionmentioning

confidence: 99%

Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: a cross-sectional survey

Heyne

Esser

Werner

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose We aim to assess attitudes toward a COVID-19 vaccine and vaccination status in cancer patients and to explore additional factors such as the level of information and comprehensibility and accessibility of this information, anxiety symptoms in general and toward COVID-19, and general health literacy. Methods We included 425 outpatients (mean age 61.4, age range 30–88 years, 60.5% women) of the Psychosocial Counseling Center for Cancer patients of the Department of Medical Psychology and Medical Sociology, Leipzig. We recorded attitudes toward a COVID-19 vaccine and vaccination status via self-report. The impact of psychosocial factors, including anxiety (GAD-7), COVID-19-specific anxiety (OCS; FCV-19S) and health literacy (HLS-EU-Q16) were analyzed with point-biserial correlations using Pearson’s r. Results We found that the vast majority (95.5%) reported being vaccinated against COVID-19 and that overall trust in safety and protective effects of a COVID-19 vaccine was high (90.9%). The vaccination readiness among nonvaccinated cancer survivors was low to very low with “fear of side effects” the most mentioned (72.2%) reason against a COVID-19 vaccine. There was no significant correlation between vaccination status and fear or anxiety symptomatology, and health literacy. Obsessive thoughts about COVID-19 was significantly higher in nonvaccinated cancer patients. Conclusions Majority of respondents are positive about COVID-19 vaccine, accompanied by a very high rate of COVID-19 immunization in our sample. Further studies with a larger sample of nonvaccinated cancer patients should further investigate the relationship on fear and vaccination hesitancy and align communication strategies accordingly.

show abstract

“…Indeed, colleagues of the Regina Elena Cancer Institute- Rome reported a 11% refusal rate in their cohort of 914 patients, with refusal being mostly due to fear of adverse events. 16 …”

Section: Discussionmentioning

confidence: 99%

Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center

et al. 2022

View full text Add to dashboard Cite

Background Few data are available on the safety of COVID-19 vaccines in cancer patients undergoing active cancer-directed treatment. Patients and Methods This case series analyzes outcomes in terms of adverse events in 5297 patients undergoing anti-cancer treatment who were vaccinated with anti-SARS-CoV-2 Pfizer-BioNTech vaccine at a single cancer center from March 6, 2021 to May 9, 2021. Adverse events were retrieved from the national Italian pharmacovigilance platform (http://www.vigicovid.it). Results Of the 5297 patients treated for either solid tumors (87%) or onco-hematologic malignancies (13%) who were vaccinated, 8 adverse drug reactions (ADRs) were reported. One was a severe ADR and 7 were non-severe ADRs. Non-severe ADRs resolved within 48 hours. Conclusion BNT162b2 Pfizer-BioNTech vaccine was safely administered in the largest cohort of cancer patients reported to date.

show abstract

The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey

Cited by 52 publications

References 3 publications

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

Attitudes toward a COVID-19 vaccine and vaccination status in cancer patients: a cross-sectional survey

Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center

Contact Info

Product

Resources

About